Enzo Biochem agreed to a $7.5 million class action lawsuit settlement to resolve claims it failed to prevent a 2023 data breach that compromised patient information.
The Enzo Biochem settlement benefits individuals whose personal information was potentially compromised in the Enzo Biochem data breach on April 6, 2023, and who received a mailed notice from Enzo informing them their information may have been compromised.
Plaintiffs in the class action lawsuit claim Enzo Biochem failed to implement reasonable cybersecurity measures that could have prevented the data breach. The plaintiffs say that, as a result of the Enzo Biochem data breach, they suffered damages including the risk of identity theft and fraud.
Enzo Biochem is a health care company that offers diagnostic testing and other services.
Enzo Biochem hasn’t admitted any wrongdoing but agreed to a $7.5 million class action settlement to resolve these allegations.
Under the terms of the Enzo Biochem settlement, class members can receive up to $10,000 for documented losses related to the data breach. These losses can include unreimbursed fraudulent charges, identity theft expenses, credit monitoring costs, computer software expenses and other related damages.
Class members who did not experience documented damages can instead opt to receive a cash fund payment, which will be a pro rata share of the net settlement fund after documented loss claims and credit monitoring payments are paid. No documentation is required for these payments.
Regardless of which payment option they choose, all class members are eligible for two years of free credit monitoring and insurance services through Medical Shield Premium.
In addition to funding the settlement, Enzo agreed to make improvements to its data security to better protect consumer information. Promised improvements include multi-factor authentication, encryption of consumer data, improved intrusion- detection and other policy improvements.
The deadline for exclusion and objection is May 23, 2025.
The final approval hearing for the settlement is scheduled for June 10, 2025.
In order to receive settlement benefits, class members must submit a valid claim form by June 23, 2025.
Who’s Eligible
Individuals whose personal information was potentially compromised in the April 2023 network incident and who were sent a notice by Enzo that their information may have been compromised.
Potential Award
Up to $10,000 in documented expenses or a pro rata cash payout, and two years of free credit monitoring and insurance services.
Proof of Purchase
Documentation of unreimbursed losses, such as bank statements, credit card statements, receipts, bills, invoices, police reports, identity theft reports, etc.
Claim Form
NOTE: If you do not qualify for this settlement do NOT file a claim.
Remember: you are submitting your claim under penalty of perjury. You are also harming other eligible Class Members by submitting a fraudulent claim. If you’re unsure if you qualify, please read the FAQ section of the Settlement Administrator’s website to ensure you meet all standards (Top Class Actions is not a Settlement Administrator). If you don’t qualify for this settlement, check out our database of other open class action settlements you may be eligible for.
Claim Form Deadline
06/23/2025
Case Name
In re: Enzo Biochem Data Security Litigation, Case No. 2:23-cv-04282-GRB-AYS, in the U.S. District Court for the Eastern District of New York
Final Hearing
06/10/2025
Settlement Website
Claims Administrator
Settlement Administrator1650 Arch Street, Suite 2210Philadelphia, PA19103[email protected]877-447-4103
Class Counsel
Jean MartinMORGAN & MORGAN COMPLEX LITIGATION GROUP
James J. PizzirussoHAUSFELD LLP
Defense Counsel
Paul KarlsgodtRobyn FeldsteinBAKER & HOSTETLER LLP
Read About More Class Action Lawsuits & Class Action Settlements:
ATTORNEY ADVERTISING
Top Class Actions is a Proud Member of the American Bar Association
LEGAL INFORMATION IS NOT LEGAL ADVICE
Top Class Actions Legal Statement
©2008 – 2025 Top Class Actions® LLC
Various Trademarks held by their respective owners
This website is not intended for viewing or usage by European Union citizens.